Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. [artículo]
Por: Riveiro Falkenbach, Erica [Instituto de Investigación i+12]
| Villanueva, Cándida A [Instituto de Investigación imas12] | Garrido Ruiz, María Concepción [Anatomía Patológica] | Ruano Domínguez, Yolanda [Instituto de Investigación i+12] | Garcia Martin, Rosa Maria [Anatomía Patológica] | Ortiz Romero, Pablo Luis [Dermatología Médico-Quirúrgica y Venereología] | Rodríguez Peralto, José Luis [Anatomía Patológica].
Colaborador(es): Servicio de Anatomía Patológica | Instituto de Investigación imas12 | Servicio de Dermatología Médico-Quirúrgica y Venereología.
Tipo de material: 
ArtículoEditor: The Journal of investigative dermatology, 2015Descripción: 135(12):3078-3085.Recursos en línea: Solicitar documento Resumen: The era of targeted therapy has introduced a new therapeutic perspective for melanoma patients. Treatment with BRAFV600 inhibitors has improved overall and disease-free survival in metastatic melanoma patients whose tumors harbor BRAFV600 mutations. Although the BRAFV600E mutation appears to have a critical role in tumor initiation, its expression during tumor progression remains controversial. In fact, various authors claim that BRAFV600E heterogeneity is evident in melanoma tumors. Herein, we investigated the pattern of BRAFV600E expression in matched primary and metastatic samples from 140 patients. Using a combination of real-time PCR and immunohistochemical analyses, we demonstrated that BRAFV600E expression is homogeneous in melanoma tumors and hypothesized that the heterogeneity described by others might be attributable to technical issues when molecular methods are used. We also demonstrated the high efficiency of the anti-BRAFV600E VE1 antibody for the detection of BRAFV600E mutations in melanoma tumors.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC17113 (Navegar estantería) | Disponible |
Formato Vancouver:
Riveiro Falkenbach E, Villanueva CA, Garrido MC, Ruano Y, García Martín RM, Godoy E et al. Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. J Invest Dermatol. 2015 Dec;135(12):3078-3085.
PMID: 26083553
Contiene 33 referencias
The era of targeted therapy has introduced a new therapeutic perspective for melanoma patients. Treatment with BRAFV600 inhibitors has improved overall and disease-free survival in metastatic melanoma patients whose tumors harbor BRAFV600 mutations. Although the BRAFV600E mutation appears to have a critical role in tumor initiation, its expression during tumor progression remains controversial. In fact, various authors claim that BRAFV600E heterogeneity is evident in melanoma tumors. Herein, we investigated the pattern of BRAFV600E expression in matched primary and metastatic samples from 140 patients. Using a combination of real-time PCR and immunohistochemical analyses, we demonstrated that BRAFV600E expression is homogeneous in melanoma tumors and hypothesized that the heterogeneity described by others might be attributable to technical issues when molecular methods are used. We also demonstrated the high efficiency of the anti-BRAFV600E VE1 antibody for the detection of BRAFV600E mutations in melanoma tumors.
No hay comentarios para este ejemplar.